Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Overview of attention for article published in BMC Cancer, June 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 79 Dimensions

Readers on

mendeley: 61 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,275 followers.

RT @clonoSEQ: See pub on clonoSEQ analytical validation: https://t.co/ZBJrWWswCq clonoSEQ is FDA-cleared to assess MRD in patients with MM…

30 Jul 2020

Reply Repost Favourite

See pub on clonoSEQ analytical validation: https://t.co/ZBJrWWswCq clonoSEQ is FDA-cleared to assess MRD in patients with MM and B-ALL; not FDA-cleared in CLL but available as LDT from our CLIA lab. For impt info on cleared sample types + test limitations:

28 Jul 2020

Reply Repost Favourite

New article: Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. https://t.co/bRkBG4iZWu #CLL #leusm #hematology

02 Jul 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.